Diligence memo · auto-generated · as of July 2, 2026
Lomond Therapeutics Holdings, Inc.
Lomond Therapeutics Holdings, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Lomond Therapeutics Holdings, Inc. operates in Pharmaceuticals, based in DOVER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lomond Therapeutics Holdings, Inc. has raised $54M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $54M on 2024-11-01.
Most recent recorded round closed around 2024-11-01.
Valuation (modeled)modeled
Provath models Lomond Therapeutics Holdings, Inc. at approximately $420M (range $175M–$609M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 20 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 83% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.